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Longitudinal, well phenotyped, population-based cohort studies offer unique research 
opportunities in the context of genome-wide association studies (GWAS), including GWAS 
for new-onset (incident) cardiovascular disease (CVD) events, the assessment of gene x 
lifestyle interactions, and evaluating the incremental predictive utility of genetic information 
in apparently healthy individuals. Furthermore, comprehensively phenotyped community-
dwelling samples have contributed to GWAS of numerous traits that reflect normal organ 
function (e.g., cardiac structure and systolic and diastolic function) and for many traits along 
the CVD continuum (e.g., risk factors, circulating biomarkers, and subclinical disease traits). 
These GWAS have heretofore identified many genetic loci implicated in normal organ function 
and different stages of the CVD continuum. Finally, population-based cohort studies have 
made important contributions to Mendelian Randomization analyses, a statistical approach 
that uses genetic information to assess observed associations between cardiovascular traits 
and clinical CVD outcomes for potential causality.
Keywords: GwAS (genome-wide association study), population, genetic variation, genetic predisposition to 
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whAt ARe Key FeAtuReS oF PoPulAtion-BASed CohoRt 
StudieS?
As a brief introduction, we would like to highlight important design features of population-based 
studies. As opposed to hospital-based referral samples, population-based epidemiological studies 
examine community-dwelling or random samples from the general population. As such, study 
participants are not selected based on a given disease, but rather to represent the general population 
of the areas sampled, so that observations from such a sample are generalizable to the underlying 
source population. It has to be kept in mind, though, that the response rate of some landmark cohort 
studies is rather low [e.g., 5,5% for the UK Biobank (1)], which increases the potential for selection bias 
(2). Furthermore, most population-based studies are longitudinal studies that are re-examining their 
participants every few years so that repeated measures of several traits are available and trajectories 
over time (and their genetic underpinning) can be assessed, as opposed to analyses of single occasion 
measurements of select traits in typical referral samples. Thus, population-based cohort studies include 
many individuals free of the disease of interest at the beginning of the study, but who might develop the 
condition of interest over the course of the study. Therefore, population-based cohort studies are ideal 
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to study risk factors and intermediate traits for the development 
of chronic disease conditions and to estimate measures of disease 
incidence (3, 4).
Third, many population-based cohort studies perform deep 
physiological/clinical and molecular phenotyping of their study 
participants (5). For example, comprehensive physiological, 
biochemical, subclinical, and clinical measurements are 
obtained on the participants using highly standardized methods. 
Similarly, clinical endpoints are adjudicated in a comprehensive 
and highly standardized process, which enhances the accuracy 
and validity of endpoint data from population-based cohort 
studies. The molecular characterization may include the 
assessment of common and rare genetic variation and other 
OMICs measurements, such as epigenomics, transcriptomics, 
lipidomics, proteomics, and metabolomics (5). These key features 
of population-based studies allow specific research questions 
to be addressed in the context of genome-wide association 
studies (GWAS). For example, the detailed phenotyping allows 
comprehensive adjustments and mediation analyses in order to 
delineate whether an observed association between a genetic 
variant and cardiovascular outcomes is independent of traditional 
risk factors and whether traditional risk factors or biomarkers 
might mediate the observed association. Overall, population-
based studies have made a substantial contribution to scientific 
discoveries in the GWAS era. A few illustrative highlights of such 
findings from cohort studies are described below.
ReFeRenCe SAmPle FoR GenetiC-
ePidemioloGiCAl AnAlySeS
Since many community-dwelling samples are representative of the 
general population, population-based studies have served as reference 
(“control”) samples for many genetic case-control analyses. In essence, 
genetic case-control studies compare allelic frequencies of genetic 
variants in prevalent cases (patients who have the disease of interest 
when they are sampled) and controls. Ideally, the control sample 
captures the distribution of the exposure (in this case, the allele 
frequencies of putative genetic variants) in the source population from 
which the cases were derived (6). Therefore, population-based studies 
have provided controls for genetic case-control studies of a broad 
spectrum of traits, including myocardial infarction (MI)/coronary 
artery disease (CAD) (7), stroke  (8, 9), and dilated cardiomyopathy 
(10). Importantly, as detailed below, GWAS might reveal different 
results depending on whether prevalent or incident cases are being 
analyzed.
GwAS AnAlySeS FoR A BRoAd 
SPeCtRum oF PhenotyPiC tRAitS 
And BiomARKeRS AlonG the 
CARdiovASCulAR diSeASe 
Continuum
The broad and highly standardized phenotyping of their 
study participants has allowed many different contributions of 
population-based cohort studies to GWAS. Specifically, researchers 
from population-based studies have performed and contributed 
to numerous GWAS for traits along the cardiovascular disease 
continuum, including traditional CVD risk factors [e.g., lipids 
(11), blood pressure (12, 13), and glycemic traits (14)], circulating 
cardiovascular biomarkers [e.g., B-type natriuretic peptide (BNP) 
(15), C-reactive protein (16), troponin (17), aldosterone, renin 
concentration, renin activity (18), adipokines (19), and fibrinogen 
levels (20)], and subclinical cardiovascular disease traits [such as 
indices of left ventricular structure and function (21, 22), carotid 
intima media thickness [IMT] (23), and coronary artery calcification 
(24)]. Of note, cardiac function can be assessed by different 
modalities, including e.g., ECG, echocardiography, MRI/CT and 
circulating biomarkers; and genome-wide genetic analyses have 
been conducted for various of these traits, including ECG parameters 
(25), echocardiographic traits (21, 22) and MRI measures of cardiac 
structure and function (26), as well as relevant biomarkers (15). 
It is important to keep in mind that community-based samples (as 
opposed to clinical samples with established disease) include many 
individuals free of CVD at the time of inclusion in the study so that 
population-based cohort studies offer great opportunities to study 
the development of cardiovascular disease conditions over the adult 
life course (27), including very early (clinically asymptomatic) stages 
of the disease process and the genetic underpinning of these early 
stages. Thus, the above-mentioned GWAS have described to what 
extent different stages along the CVD continuum are associated with 
genetic variation and which genes might be involved.
Furthermore, given the large proportion of apparently healthy 
individuals in population-based cohort studies (as opposed 
to clinical samples), these studies conducted GWAS of many 
traits that reflect relatively normal organ function, including 
biomarkers of cardiac structure and systolic and diastolic 
function (21, 22). These studies provided important insights how 
physiological organ function is influenced by genetic variation, 
and how organ dysfunction might contribute to different disease 
processes (21, 22).
ASSeSSment oF Gene X liFeStyle 
inteRACtionS
It is an important and growing area of research to quantify the 
contribution of genes and of different lifestyle factors (and their 
interactions) to inter-individual variation in cardiovascular risk factor 
levels and disease risk. Since well phenotyped cohort studies usually 
have comprehensive genetic data and detailed lifestyle information 
available, population-based studies represent an ideal setting to study 
gene x lifestyle interactions. The interaction of a genetic risk score 
(based on 50 SNPs) and a lifestyle score (including information on 
smoking, obesity, physical activity, and diet) on the incidence of 
CAD has been analyzed in several large community-based cohorts 
(28). Key observations from these analyses were that (i) both scores, 
the genetic risk score and the lifestyle score, were independently 
associated with the risk of incident CVD and that (ii) a favorable 
lifestyle was associated with an almost 50% reduction in the relative 
risk for CAD, as compared to those with an unfavorable lifestyle 
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profile (28). This reduction in the relative risk of CAD by a favorable 
lifestyle was observed in individuals with high genetic risk, but also 
in individuals with low and intermediate genetic risk (28). Very 
similar observations were made in more than 270.000 participants 
of the UK Biobank, when a polygenic risk score, representing 
314 BP-associated loci, as well as a slightly different lifestyle score 
(including information on body mass index, healthy diet, sedentary 
lifestyle, alcohol consumption, smoking, and urinary sodium 
excretion levels) were related to different BP traits and to incident 
CVD (29). Both, the genetic risk score as well as the lifestyle score were 
associated with BP traits and incident CVD. Importantly, a favorable 
lifestyle as compared to an unfavorable lifestyle was associated with 
substantially lower average BP values in all categories of genetic risk 
(low, intermediate, high) and with an about 30% lower relative risk 
for incident CVD (29). 
The same lifestyle score as in Reference (28) was used in a sample 
of young women (aged 25 to 40 years) from the Dutch Lifelines cohort 
to assess the contribution of rare and common genetic variation and 
of lifestyle factors to very low (≤1st age- and sex-specific percentile) 
and very high (≥99% age- and sex-specific percentile) levels of LDL-C. 
The study revealed that about two thirds of the women with very low 
LDL-C levels had a likely genetic cause (either a relevant mutation 
in an established gene for monogenic hypocholesterolemia or a very 
low polygenic risk score), whereas the lifestyle score (28) was not 
statistically significantly associated with low LDL-C concentrations 
(30). In cases with hypercholesterolemia, however, an unfavorable 
lifestyle seems to be more relevant. Only about 40% of the women 
had a genetic cause (relevant mutations in genes for monogenic 
familial hypercholesterolemia) or predisposition (high polygenic 
risk score) for high LDL-C; and of the women without genetic cause 
for hypercholesterolemia, more than half of women displayed an 
unfavorable lifestyle profile (30).
Community-based studies have also been involved in studying 
uncommon loss-of-function variants that may offer insights into 
function of variants. For example, (gain-of-function) mutations in the 
PCSK9 (proprotein convertase subtilisin/kexin type 9) serine protease 
gene were initially identified in families with autosomal dominant 
hypercholesterolemia (31). Subsequently, loss-of-function mutations 
were reported in individuals with low circulating low-density 
lipoprotein (LDL) cholesterol levels (32). Analyses in population-
based studies revealed that low-frequency sequence variants in the 
PCSK9 gene and a PCSK9 genetic score were associated with lower 
circulating LDL cholesterol levels and reduced risk of cardiovascular 
events in the general population (33, 34). Recently, PCSK9 inhibitors 
have been tested in randomized controlled trials (35).
the GenetiC undeRPinninG oF 
ChAnGe in CARdiovASCulAR tRAitS 
oveR the liFe CouRSe
Due to the availability of repeated measures over time, cohort studies 
are also suitable to explore the genetic underpinning of changes 
in cardiovascular risk factors over time, and of the progression of 
subclinical CVD traits longitudinally. For example, a GWAS for 
carotid IMT measured at different time points over a 10-year period 
has recently been published (36). Furthermore, several researchers 
assessed the association of risk factor-associated genetic variants 
with trajectories of the respective risk factor over the life course. 
For example, BMI-associated genetic variants have been related 
to repeated measures of BMI over time (37). Interestingly, BMI 
in childhood and adulthood were associated with different sets of 
single nucleotide polymorphisms (SNPs) (37), respectively, consistent 
with the concept that genetic effects on risk factors might be age-
dependent. In line with this concept, genetic linkage analyses for BMI 
provided evidence for age-dependent effects of select genetic loci (38).
On a parallel note, a genetic risk score consisting of 29 SNPs was 
not only associated with blood pressure and hypertension prevalence 
at baseline, but also with new-onset hypertension and change in blood 
pressure over the life course in a large Swedish cohort study (39).
GwAS FoR inCident diSeASe 
ConditionS
The longitudinal character of population-based cohort studies allows 
genetic variation to be studied in relation to disease incidence. For 
example, population-based cohort studies have facilitated GWAS 
for incident heart failure (40), incident stroke (41) and incident MI/
coronary heart disease (CHD) (3). Interestingly, GWAS for incident 
MI/CHD (3) reported partially discrepant results as compared to 
GWAS using prevalent CAD cases (7). As an example, the chromosome 
9p21 locus – consistently replicated in case-control GWAS for CAD/
MI (7, 42) – provided only modest evidence for association in a GWAS 
for incident MI/CHD within the CHARGE consortium (3). Of note, 
the CHARGE consortium (Cohorts for Heart and Aging Research 
in Genomic Epidemiology) was founded to coordinate joint GWAS 
analyses of several traits in large population-based cohort studies and 
to provide opportunities for mutual replication efforts (43).
It is well known that analyses based on prevalent disease cases 
and those based on incident cases might reveal different results if 
the association between an exposure and the disease outcome differs 
by disease severity or disease duration (a phenomenon referred to 
as prevalence-incidence bias) (44). In order to be included in a case-
control study as prevalent MI/CAD case, MI patients have to survive 
the acute event until they are sampled. Given that MI is still associated 
with substantial case fatality (45, 46), case-control studies are likely 
enriched for MI/CAD survivors with rather long survival (3). Thus, 
alleles associated with prevalent CAD in case-control analyses could 
be related to the risk of developing the CAD event, but could also be 
related to the chances of surviving the acute CAD event. In line with 
this concept, the CAD risk allele at the 9p21 locus was associated 
with longer survival after MI in several population-based cohorts 
within CHARGE (3).
imPACt oF GenetiC vARiAtion on RiSK 
PRediCtion
Furthermore, community-based prospective cohorts allow assessing 
whether genetic information improves risk prediction models beyond 
traditional risk factors. It was, indeed, one of the main motivations 
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of the human genome project to use genetic information to predict 
disease risks in healthy individuals and to predict the response 
to a given therapy among patients. Several analyses conducted in 
various population-based cohorts assessed whether genetic variation 
– e.g., in an aggregated form as risk scores – improved performance 
measures of risk prediction models for a first CVD event, including 
discrimination, calibration, and reclassification (47–50). Although 
the results from individual studies vary, in most cases, the genetic risk 
scores displayed clear statistically significant associations with CVD 
endpoints, but improvements in discrimination (e.g., C-statistics; 
integrated discrimination improvement) and reclassification (e.g., net 
reclassification index) were more modest (47, 48) and some studies 
did not provide evidence for improvement in these performance 
metrices beyond traditional risk factors (49, 50).
mendeliAn RAndomizAtion AnAlySeS 
FoR CARdiovASCulAR tRAitS
Genetic information in population-based cohort studies has also 
been used to assess causality between cardiovascular risk factors or 
circulating biomarkers and cardiovascular outcomes (incident CVD 
events) using instrumental variable analyses, a statistical approach 
referred to as Mendelian Randomization (MR) (51–53). This term, 
MR, refers to the random assortment of alleles of a given locus at 
meiosis (51, 52). Thus, if a genetic locus (or a genetic risk score) 
is strongly associated with circulating biomarker levels or with risk 
factor levels, individuals are “randomized” to genetically determined 
high or low biomarker/risk factor levels (51, 52, 54). If the biomarker/
risk factor is causally related to CVD, this difference in genetically 
determined higher or lower biomarker/risk factor levels should 
translate into corresponding quantitative differences in disease risk 
(51, 52, 54). Therefore, in addition to the association between the 
genetic variant and the risk factor/biomarker of interest, MR analyses 
also assess the associations between the risk factor/biomarker and 
incident CVD as well as between the genetic variant and incident 
CVD (52); the two latter analyses are facilitated by population-based 
cohort studies. By using genetic information as instrumental variable 
for the biomarker/risk factor of interest, MR analyses try to avoid 
two important limitations of observational studies, reverse causality 
and confounding (54, 55). Using MR analyses in population-based 
samples, several traits along the CVD continuum and biomarkers 
have been tested for potentially causal relations with incident CVD, 
including high-density lipoprotein (HDL) cholesterol (53), C-reactive 
protein (56), lipoprotein(a) (57), and many others. It has to be kept 
in mind, though, that instrumental variable analyses can be affected 
by different types of selection bias. For example, such analyses might 
be biased, if a genetic variant is related to mortality, and MR analyses 
are conducted in an elderly sample (58, 59).
ConCluSion
Population-based studies have substantially improved our 
understanding of the genetic architecture of normal and abnormal 
organ function, CVD risk factors, circulating biomarkers, subclinical 
disease, and overt CVD traits over the life course. Furthermore, 
they were essential in exploring gene x lifestyle interactions and 
in evaluating genetic variation in the context of risk prediction 
models for incident CVD. In addition, population-based cohort 
studies provided great opportunities to conduct GWAS for incident 
CVD events, such as MI, stroke and heart failure, and thereby, to 
overcome classic limitations of case-control GWAS including 
prevalence-incidence bias. Finally, population-based cohort studies 
used genetic information as instrumental variables to assess whether 
cardiovascular risk factors or biomarkers are causally related to 
clinical CVD (Mendelian Randomization analyses).
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